Researchers at Brigham Young University have announced a pre‑clinical breakthrough in cancer immunotherapy. Their newly created platform, named MOTO‑CAR, genetically reprograms a patient’s own immune cells so they can identify and destroy cancer cells. In laboratory experiments, the team observed a 90% decline in aggressive lung cancer cells within 24 hours of exposure to the engineered cells, according to the university’s report.
How MOTO‑CAR Works and Lab Results
The MOTO‑CAR system modifies immune cells at the genetic level, giving them the ability to recognize markers specific to cancerous tissue. In the reported study, the engineered cells were introduced to cultures of aggressive lung cancer lines. Within a single day, the number of viable cancer cells fell by nine‑tenths, a reduction the researchers described as “significant” for a first‑in‑the‑lab test. The rapid effect suggests the engineered cells can act quickly once they encounter target tumors.
Potential Benefits and Affordability Goal
Kim O’Neill, a BYU professor of microbiology and molecular biology and a lead investigator on the project, emphasized the broader aim of the work. “Our unique MOTO‑CAR technology is designed to convert the patient’s own immune system to recognize and fight the cancer,” O’Neill said. She added that the team hopes the approach can be produced at a lower cost than many existing treatments, potentially making it accessible worldwide. If the technology proves effective in humans, it could lessen reliance on traditional interventions such as surgery, chemotherapy, or radiation, which often carry high financial and side‑effect burdens.
Next Steps Toward Human Trials
While the laboratory findings are encouraging, the researchers caution that significant development remains before the therapy can be tested in patients. Additional pre‑clinical work is required to confirm safety, determine optimal dosing, and assess long‑term effects. Only after these hurdles are cleared will the team consider moving into clinical trial phases. O’Neill reiterated that the current results represent an early stage, noting that “more work is needed before human trials can begin.”
The BYU team’s announcement adds to a growing field of cell‑based cancer therapies that aim to harness the body’s own defenses. By focusing on genetic engineering of immune cells, MOTO‑CAR aligns with broader efforts to create personalized, targeted treatments. The reported 90% reduction in lung cancer cells within a day provides a measurable benchmark for future research and may guide subsequent experiments aimed at scaling the technology.
Stakeholders in the oncology community will likely monitor the progress of MOTO‑CAR closely, especially given the stated intent to keep costs low. If the platform can be translated from the lab bench to clinical practice, it could represent a shift toward more affordable, less invasive cancer care worldwide.
Mitchell Landsberg is a Senior Technology Correspondent at News Raise. He covers consumer electronics, artificial intelligence, software developments, and digital privacy trends.
